RnDCircle Logo
최영진 연구실
충북대학교 의학과
최영진 교수
기본 정보
연구 분야
논문
구성원

최영진 연구실

충북대학교 의학과 최영진 교수

최영진 연구실은 유방암과 유방내분비 질환을 중심으로 한 외과종양학 연구를 수행하며, 감시림프절생검·액와부 수술·유두보존유방절제술 등 유방외과 술식의 임상적 최적화, 외과초음파 기반 정밀 진단 및 수술 유도 기술, 그리고 다양한 암종에서의 예후 예측과 치료반응 평가를 위한 임상종양학 연구를 통해 환자 맞춤형 암 치료의 근거를 축적하고 있다.

대표 연구 분야
연구 영역 전체보기
유방암 외과치료와 유방내분비 종양 연구 thumbnail
유방암 외과치료와 유방내분비 종양 연구
연구 성과 추이
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.

5개년 연도별 논문 게재 수

25총합

5개년 연도별 피인용 수

163총합
주요 논문
3
논문 전체보기
1
article
|
인용수 0
·
2025
2624P Artificial intelligence (AI)-powered immune phenotype (IP) predicts differential benefit from nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) in advanced clear cell renal cell carcinoma (ccRCC)
C.G. Kim, Minkyu Jung, Jae‐Hun Kim, Hee Sang Hwang, Mao Jimin, G. Park, Young Jin Choi, S-H. Beom, Sun Young Rha, Saeam Shin, Jia-Lin Lee, Seung Kew Yoon, Beung‐Chul Ahn, Seok‐Geun Lee, Y.M. Cho, Jae Hyoung Park, Il Park
IF 65.4
Annals of Oncology
https://doi.org/10.1016/j.annonc.2025.08.3239
Ipilimumab
Nivolumab
Sunitinib
Clear cell renal cell carcinoma
Renal cell carcinoma
Kidney cancer
Immunotherapy
Immune system
2
article
|
gold
·
인용수 1
·
2023
An observational, prospective, open label, multicenter study to evaluate the safety and effectiveness of pegfilgrastim as secondary prophylaxis to decrease the incidence of febrile neutropenia in Korean female patients with breast cancer
Anbok Lee, Taewoo Kang, Su Hwan Kang, Woo Chan Park, Woosung Lim, Myung-Chul Chang, Hyun Yul Kim, Jeong-Yoon Song, Jihyoun Lee, Kyung Do Byun, Hyun‐Ah Kim, Gil Soo Son, Ju‐Yeon Kim, Se Jeong Oh, Min Sung Chung, Young Jin Choi, Hyukjai Shin, Jong Min Baek, Young-Bum Yoo, Eunhae Um, Jin‐Hyuk Choi, Beom Seok Kwak, Min Ho Park, Suok Hyun Lee, Cheol Seung Kim, Ilkyun Lee, Je Ryong Kim, Han Shin Lee, Cheol Wan Lim
IF 7.9
The Breast
The use of pegfilgrastim as secondary prophylaxis was effective and safe for preventing FN in patients with breast cancer who were treated with chemotherapy.
https://doi.org/10.1016/j.breast.2023.103585
Pegfilgrastim
Medicine
Febrile neutropenia
Internal medicine
Clinical endpoint
Breast cancer
Neutropenia
Bone pain
Incidence (geometry)
Adverse effect
3
article
|
인용수 0
·
2022
Abstract P3-12-25: Risk of second primary cancers after curative treatment of breast cancer: A Korean nationwide population-based study
Haeyoung Kim, Su Ssan Kim, Ji Sung Lee, Jae Sun Yoon, Hyuk Jai Shin, Jeong Eon Lee, Sei Kyung Lee, Il Yong Chung, So‐Youn Jung, Young Jin Choi, Korean Breast Cancer Society
IF 16.6
Cancer Research
Abstract Purpose:This study was performed to analyze the risk of second non-breast primary cancers (2nd_PrimaryCa) among Korean women who had received curative treatment for breast cancer. Methods:By using data from the Korean National Health Insurance Service Database between 2002 and 2017, we identified 399,621 women with invasive breast cancer. To analyze the long-term risk of 2nd_PrimaryCa, we included 52,506 women who underwent curative surgery between 2003 and 2008, and no history of cancers before the date of breast cancer surgery. The cumulative incidence of 2nd_PrimaryCa was estimated using the Kaplan-Meier analysis. Cox regression analysis was used to analyze the association between 2nd_PrimaryCa occurrence and factors including age, income level, receipt of systemic treatment or radiotherapy, family history of cancers, alcohol intake, and BRCA gene mutations.Results:A total of 3,084 (5.87%) patients developed 2nd_PrimaryCa. The 10-year incidence of 2nd_PrimaryCa was 5.78% (range, 5.56 – 6.00%). The median time to 2nd_PrimaryCa was 7.61 years (range, 6.22 – 9.31 years). Types of organs involved by 2nd_PrimaryCa were as followings: thyroid (18.84%), gynecological organs (12.78%), hepatobiliary structures (12.48%), thorax (11.25%), lower gastrointestinal (GI) tract (9.63%), upper GI tract (9.18%), skin (4.22%), lymphoma or leukemia (4.09%), brain (3.15%), head and neck (2.56%), and others (11.84%). The risk of 2nd_PrimaryCa was significantly associated with ≥ 60 years of age (hazard ratio (HR) = 2.15, 95% confidence interval (CI) = 1.60 – 2.90, p < 0.01), Medical Aid recipients (HR = 8.79, 95% CI = 6.73 – 10.85, p < 0.01), and receipt of chemotherapy and endocrine therapy (HR = 1.27, 95% CI = 1.12 – 1.43, p < 0.01). Radiotherapy was related to lower incidence of 2nd_PrimaryCa (HR = 0.87, 95% CI = 0.81 – 0.94, p < 0.01). Alcohol intake, family history of cancer, or carrying BRCA gene mutations was not related to the risk of 2nd_PrimaryCa. Among the patients with 2nd_PrimaryCa, the 5-year overall survival (OS) rate was 67.28% after the diagnosis of 2nd_PrimaryCa. Age of ≥ 60 years (HR = 1.67, 95% CI = 1.01 – 2.78, p = 0.04) and receiving chemotherapy and endocrine therapy (HR = 1.88, 95% CI = 1.43 – 2.46, p < 0.01) were significantly related to inferior OS. Conclusions:The risk of 2nd_PrimaryCa was associated with personal and treatment factors in Korean patients with breast cancer. These factors are needed to be considered in the surveillance of breast cancer survivors. Citation Format: Haeyoung Kim, Su SSan Kim, Ji Sung Lee, Jae Sun Yoon, Hyuk Jai Shin, Jeong Eon Lee, Sei Kyung Lee, Il Yong Chung, So-Youn Jung, Young Jin Choi, Korean Breast Cancer Society. Risk of second primary cancers after curative treatment of breast cancer: A Korean nationwide population-based study [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P3-12-25.
https://doi.org/10.1158/1538-7445.sabcs21-p3-12-25
Medicine
Breast cancer
Hazard ratio
Internal medicine
Cancer
Incidence (geometry)
Proportional hazards model
Oncology
Population
Confidence interval